Detailed Information

Cited 0 time in webofscience Cited 0 time in scopus
Metadata Downloads

Rivoceranib, a VEGFR-2 inhibitor, monotherapy in previously treated patients with advanced or metastatic gastric or gastroesophageal junction cancer (ANGEL study): an international, randomized, placebo-controlled, phase 3 trial

Kang, Yoon-KooRyu, Min-HeeDi Bartolomeo, MariaChau, IanYoon, HarryKim, Jong GwangLee, Keun-WookOh, Sang ChulTakashima, AtsuoKryzhanivska, AnnaChao, YeeEvesque, LudovicSchenker, MichaelMcginn, ArloZhao, YufanLee, JenniferWyrwicz, LucjanBoku, Narikazu
Issue Date
Springer Verlag
Stomach neoplasms; Tyrosine protein kinase inhibitors; Vascular endothelial growth factor receptor-2
Gastric Cancer
Journal Title
Gastric Cancer
Background Rivoceranib is an oral, selective tyrosine kinase inhibitor of vascular endothelial growth factor receptor-2. ANGEL (NCT03042611) was a global, randomized, double-blinded, placebo-controlled, phase 3 study evaluating rivoceranib as 3rd-line or >= 4th-line therapy in patients with advanced/metastatic gastric or gastroesophageal junction (GEJ) cancer. Methods Patients had failed >= 2 lines of chemotherapy and were randomized 2:1 to rivoceranib 700 mg once daily or placebo with best supportive care. Primary endpoint: overall survival (OS) in the intention-to-treat population. Secondary endpoints: progression-free survival (PFS), objective response rate (ORR), and disease control rate (DCR) by blinded independent central review (BICR). Results In total, 460 patients (rivoceranib n = 308, placebo n = 152) were enrolled. OS was not statistically different for rivoceranib versus placebo (median 5.78 vs. 5.13 months; hazard ratio [HR] 0.93, 95% CI 0.74-1.15; p = 0.4724). PFS by BICR (median 2.83 vs. 1.77 months; HR 0.58, 95% CI 0.47-0.71; p < 0.0001), ORR (6.5% vs. 1.3%; p = 0.0119), and DCR (40.3 vs. 13.2%; p < 0.0001) were improved with rivoceranib versus placebo. In patients receiving >= 4th-line therapy, OS (median 6.34 vs. 4.73 months; p = 0.0192) and PFS by BICR (median 3.52 vs. 1.71 months; p < 0.0001) were improved with rivoceranib versus placebo. The most common grade >= 3 treatment-emergent adverse events with rivoceranib were hypertension (17.9%), anemia (10.4%), aspartate aminotransferase increased (9.4%), asthenia (8.5%), and proteinuria (7.5%). Conclusions This study did not meet its primary OS endpoint. Compared to placebo, rivoceranib improved PFS, ORR, and DCR. Rivoceranib also improved OS in a prespecified patient subgroup receiving >= 4th-line therapy.
Files in This Item
There are no files associated with this item.
Appears in
5. Others > ETC > 1. Journal Articles


Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.

Related Researcher

Researcher Oh, Sang Cheul photo

Oh, Sang Cheul
Guro Hospital (Department of Medical Oncology and Hematology, Guro Hospital)
Read more


Total Views & Downloads